EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis

Christina Koenig iD, Marguerite L Monogue iD, Ryan K Shields iD, Colleen M Sakon, Andrew J Fratoni, Hanna F Roenfanz, James D Finklea, James S Pope, David P Nicolau iD, Joseph L Kuti iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01539-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Christina Koenig und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cephalosporins, Anti-Bacterial Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi (Shionogi & Co. Ltd.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persons with CF (pwCF) present altered pharmacokinetics (PK) and are often infected with multidrug-resistant (MDR) bacteria. Herein, we describe the PK of cefiderocol, a siderophore cephalosporin with potent activity against MDR Gram-negative rods, in hospitalized adult pwCF with acute pulmonary exacerbation (APE). PwCF received ≥3 doses of 2 g cefiderocol (3 h infusion) with frequency determined according to their estimated glomerular filtration rate (eGFR). Blood sampling collected at steady state. Concentrations were fitted using the non-parametric adaptive grid algorithm in Pmetrics for R. Ten pwCF were enrolled; nine completed the study with six receiving 2 g q8 h and three 2 g q6 h. A two-compartment model best fitted the data. Mean (SD) PK parameters were clearance, 5.66 (1.28) L/h; volume of central compartment, 5.81 (3.52) L, and intercompartment transfer constants, k12, 4.29 (3.46) and k21, 2.25 (2.76) h −1 . Protein binding was 48% (35–57). The 2 g q8 h regimen achieved a mean free time above the MIC ( f T >MIC) of 99% (94–99), 90% (69–100), and 64% (41–81) at MICs of 4 (susceptible), 8 (intermediate), and 16 (resistant) mg/L, respectively, with AUC 24h of 1,191 (781–1,496) mg/L*h. In pwCF with eGFR >120 mL/min, 2 g q6 h attained 100% f T >MIC up to 8 mg/L and 87% (83–92) at 16 mg/L, with AUC 24h of 1,279 (1,054–1,590) mg/L*h. Among these nine pwCF with APE with normal or augmented renal clearance, cefiderocol using label prescribed dosing regimens according to eGFR was well tolerated and achieved optimal f T >MIC exposure for pathogens up to MICs of 8 mg/L and AUC 24h estimates similar to previously reported estimates in non-CF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCephalosporinsAnti-Bacterial AgentsHumansAdultCefiderocolMaleFemaleMicrobial Sensitivity TestsMiddle AgedGlomerular Filtration RateHospitalizationYoung Adult

Stichwörter der Autor:innen

beta-lactamcefiderocolcystic fibrosispharmacokinetics

Substanzen

CephalosporinsAnti-Bacterial AgentsCefiderocol

Autor:innen und Institutionen

  • Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Indiana University Health, Indianapolis, Indiana, USA.
  • Division of Pulmonary and Critical Care Medicine, Hartford Hospital, Hartford, Connecticut, USA.

ORCID-Profile: Christina Koenig, Marguerite L Monogue, Ryan K Shields, David P Nicolau, Joseph L Kuti

Förderung

  • Shionogi (Shionogi & Co. Ltd.)

Zitieren

APA

Koenig, C., Monogue, M. L., Shields, R. K., Sakon, C. M., Fratoni, A. J., Roenfanz, H. F., Finklea, J. D., Pope, J. S., Nicolau, D. P., & Kuti, J. L. (2025). Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01539-24

Vancouver

Koenig C, Monogue ML, Shields RK, Sakon CM, Fratoni AJ, Roenfanz HF, et al. Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01539-24

BibTeX
@article{Koenig2025,
  author = {Koenig, Christina and Monogue, Marguerite L and Shields, Ryan K and Sakon, Colleen M and Fratoni, Andrew J and Roenfanz, Hanna F and Finklea, James D and Pope, James S and Nicolau, David P and Kuti, Joseph L},
  title = {Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01539-24}
}
Kostenlos starten →